Table 1.
Baseline characteristics of PD-1 treated advanced melanoma patients.
| Sex | |
| • Male | 119 (62.6%) |
| Age | |
| • Median (range) | 68 (20–91) |
| • ≤60 | 63 (33.2%) |
| • 60 to ≤70 | 55 (28.9%) |
| • >70 | 72 (37.9%) |
| BMI | |
| • <25 | 53 (27.9%) |
| • 25-30 | 65 (34.2%) |
| • >30.0 | 72 (37.9%) |
| Histology | |
| • Cutaneous | 145 (76.3%) |
| • Unknown primary | 30 (15.8%) |
| • Mucosal | 15 (7.9%) |
| ECOG PS | |
| • 0-1 | 163 (85.8%) |
| • 2 | 11 (5.8%) |
| • ≥3 | 2 (1.0%) |
| • NR | 14 (7.4%) |
| Prior autoimmune disease | 23 (16.0%) |
| Extent of disease | |
| • Unresectable stage III | 28 (14.7%) |
| • M1a | 26 (13.7%) |
| • M1b | 28 (14.7%) |
| • M1c | 59 (31.1%) |
| • M1d | 49 (25.8%) |
| Mutational status | |
| • #BRAF V600E/K | 52 (27.4%) |
| • $NRAS | 43 (22.6%) |
| LDH (ULN = 171) | |
| • Normal | 41 (21.6%) |
| • 1 to ≤2x ULN | 99 (52.1%) |
| • >2x ULN | 28 (14.7%) |
| • N/A | 22 (11.6%) |
| Anti PD-1 Agent Received | |
| • Nivolumab | 33 (17.4%) |
| • Pembrolizumab | 157 (82.6%) |
| Anti-PD-1 Line of Therapy (Advanced Setting) | |
| • 1st | 107 (56.3%) |
| • 2nd | 47 (24.7%) |
| • ≤3rd | 36 (19.0%) |
| Prior Therapy | |
| • Anti-CTLA | 68 (35.8%) |
| • Interferon | 59 (31.0%) |
| Best Response to Anti-PD-1 | |
| • CR | 36 (19.0%) |
| • PR | 55 (28.9%) |
| • SD | 25 (13.1%) |
| • PD | 74 (39.0%) |
| Current Response to Anti-PD-1 | |
| • CR | 30 (15.8%) |
| • PR | 37 (19.5%) |
| • SD | 10 (5.2%) |
| • PD | 113 (59.5%) |
#BRAF mutation status was unknown in 14 (7.3%) of patients.
$NRAS mutation status was unknown in 32 (16.9%) of patients.